Eylea is Preferred for Diabetes-Related Vision Loss

February 19, 2015 11:24 AM

15 0

The diabetic macular edema (DME) drug Eylea (aflibercept) was proved to provide greater visual improvement than Avastin (bevacizumab) or Lucentis (ranibizumab), a recent study found. This applies to a starting vision of 20/50 or worse. Nevertheless the 3 drugs mentioned above led to similar average improvement whenever starting vision was 20/40 to 20/32.

The study was conducted by the Diabetic Retinopathy Clinical Research Network, funded by the U.S. National Eye Institute (NEI), and was published online Wednesday in the New England Journal of Medicine.

Read more

To category page